Pyrazine derivatives as ENaC blockers
US9522149B2 · kind B2 · utility
0Cited by
7References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2015 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Apr 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I:and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.